Company intelligence / Profile preview

Harras Pharma Curarina

München, Bavaria, Germanyharraspharma.de ↗

Ownership: Private
Development stage: Other

Overview

The company has developed and commercialized several herbal-based medicinal products with proven efficacy and safety. Traumaplant®, a comfrey-based pain cream, has been validated in multiple clinical studies for blunt injuries. Sucontral® D for diabetes management and Sensicutan® for skin conditions are also approved and marketed internationally.

Therapeutic areas: DermatologyEndocrinologyInfectious DiseasesOther
Modalities: Herbal extract therapySmall molecule
Industry: Biotech

Drug pipeline

10 assets

Hintonia latiflora extract

9 more assets in the full pipeline.

Request access →

Partnerships

Outlicensing partners in various countries including USA, Canada, Austria, Switzerland, Peru, Slovakia, Czech Republic, England.

Beyond the preview

Go deeper on Harras Pharma Curarina.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harras Pharma Curarina.

Explore the full profile